GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: CG-400549 | CG400549
Compound class:
Synthetic organic
Comment: Nilofabicin is an antibacterial compound that functions by inhibiting bacterial enoyl-ACP reductase (FabI) [2]. It has no activity against Gram-positive bacteria.
|
|
No information available. |
Summary of Clinical Use ![]() |
Nilofabicin has completed a Phase 2 clinical study (NCT01593761) to assess efficacy in subjects with acute bacterial skin and skin structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01593761 | Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus | Phase 2 Interventional | CrystalGenomics, Inc. |